Structure based design of 11β-hsd1 inhibitors

Current Pharmaceutical Biotechnology

Volumn 11, Issue 7, 2010, Pages 779-791

  Singh, Suresh B ^a   Tice, Colin M ^a  

^a Vitae Pharmaceuticals   (United States)

Author keywords

11 hsd1; Aminothiazolones; Binding modes; Cortisol; Cortisone; Inhibitors; Metabolic syndrome; Natural products; Pharmacody namic; Structure activity relationship; Structure based drug design; Sulfonamides; Triazoles; X ray crystal structures

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; AMG 221; AMIDE; CARBENOXOLONE; ENZYME INHIBITOR; NATURAL PRODUCT; OXIDOREDUCTASE INHIBITOR; SULFONAMIDE; TRIAZOLE; TRITERPENE 18 BETA GLYCYRRHETINIC ACID; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HYDROGEN BOND; IC 50; NONHUMAN; PROTEIN STRUCTURE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; CLINICAL TRIALS AS TOPIC; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; METABOLIC SYNDROME X; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78649314111     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110792927748     Document Type: Article

References (85)

1. Alberti, K. G. M. M.; Eckel, R. H.; Grundy, S. M.; Zimmet, P. Z.; Cleeman, J. I.; Donato, K. A.; Fruchart, J.-C.; James, W. P. T.; Loria, C. M.; Smith, S. C. Jr., Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009, 120(16), 1640-1645.
2. Fotsch, C.; Wang, M. Blockade of glucocorticoid excess at the tissue level: inhibitors of 11Beta -hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes. J.Med. Chem., 2008, 51(16), 4851-4857.
3. Wamil, M.; Seckl, J. R. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov. Today, 2007, 12(13&14), 504-520.
4. Cooper, M. S.; Stewart, P. M. 11beta -hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J. Clin. Endocrinol.Metabol., 2009, 94(12), 4645-4654.
5. Morton, N.M. Obesity and corticosteroids: 11.beta -Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol.Cell. Endocrinol., 2010, 316(2), 154-164.
6. Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N. M.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. A transgenic model of visceral obesity and the metabolic syndrome. Science (Washington, DC, United States) 2001, 294(5549), 2166-2170.
7. Masuzaki, H.; Yamamoto, H.; Kenyon, C. J.; Elmquist, J. K.; Morton, N. M.; Paterson, J. M.; Shinyama, H.; Sharp, M. G. F.; Fleming, S.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Investig., 2003, 112(1), 83-90.
8. Kotelevitsev, Y.; Holmes, M. C.; Burchell, A.; Houston, P. M.; Schmoll, D.; Jamieson, P.; Best, R.; Brown, R.; Edwards, C. R. W.; Seckl, J. R.; Mullins, J. J. 11beta -Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA, 1997, 94(26), 14924-14929.
9. Morton, N. M.; Holmes, M. C.; Fievet, C.; Staels, B.; Tailleux, A.; Mullins, J. J.; Seckl, J. R. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta - hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem., 2001, 276(44), 41293-41300.
10. Morton, N. M.; Paterson, J. M.; Masuzaki, H.; Holmes, M. C.; Staels, B.; Fievet, C.; Walker, B. R.; Flier, J. S.; Mullins, J. J.; Seckl, J. R. Novel adipose tissue-mediated resistance to diet- induced visceral obesity in 11beta -hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes, 2004, 53(4), 931-938.
11. Bhat, B. G.; Younis, H.; Herrera, J.; Palacio, K.; Pascual, B.; Hur, G.; Jessen, B.; Ogilvie, K. M.; Rejto, P. A. Antisense inhibition of 11beta hydroxysteroid dehydrogenase type 1 improves diabetes in a novel cortisone-induced diabetic KK mouse model. Biochem. Biophy. Res. Commun., 2008, 365(4), 740-745.
12. Arampatzis, S.; Kadereit, B.; Schuster, D.; Balazs, Z.; Schweizer, R. A. S.; Frey, F. J.; Langer, T.; Odermatt, A. Comparative enzymology of 11beta -hydroxysteroid dehydrogenase type 1 from six species. J. Mol. Endocrinol., 2005, 35(1), 89-101.
13. Seckl, J. R.; Walker, B. R. Minireview: 11beta -hydroxysteroid dehydrogenase type 1 - A tissue-specific amplifier of glucocorticoid action. Endocrinology, 2001, 142(4), 1371-1376.
14. Wang, Z.; Wang, M. Structure and inhibitor binding mechanisms of 11.beta -hydroxysteroid dehydrogenase type 1. Curr. Chem. Biol.,2009, 3(2), 159-170.
15. Maser, E.; Voelker, B.; Friebertshaeuser, J. 11beta -hydroxysteroid dehydrogenase type 1 from human liver: Dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry 2002, 41(7), 2459-2465.
16. Greene, L. H.; Lewis, T. E.; Addou, S.; Cuff, A.; Dallman, T.; Dibley, M.; Redfern, O.; Pearl, F.; Nambudiry, R.; Reid, A.; Sillitoe, I.; Yeats, C.; Thornton, J. M.; Orengo, C. A. The CATH domain structure database: new protocols and classification levels give a more comprehensive resource for exploring evolution. Nucleic Acids Res., 2007, 35(Database Iss), D291-D297.
17. Penning, T. M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr. Rev., 1997, 18(3), 281-305.
18. Castro, A.; Zhu, J. X.; Alton, G. R.; Rejto, P.; Ermolieff, J. Assay optimization and kinetic profile of the human and the rabbit isoforms of 11beta -HSD1. Biochem.Biophys. Res. Commun., 2007, 357(2), 561-566.
19. Sahni-Arya, B.; Flynn, M. J.; Bergeron, L.; Salyan, M. E. K.; Pedicord, D. L.; Golla, R.; Ma, Z.; Wang, H.; Seethala, R.; Wu, S. C.; Li, J. J.; Nayeem, A.; Gates, C.; Hamann, L. G.; Gordon, D. A.; Blat, Y. Cofactor-specific modulation of 11beta -hydroxysteroid dehydrogenase 1 inhibitor potency. Biochim. Biophy. Acta, Proteins Proteomics, 2007, 1774(9), 1184-1191.
20. Wu, Y. D.; Houk, K. N. Theoretical study of conformational features of NAD+ and NADH analogs: protonated nicotinamide and 1,4-dihydronicotinamide. J. Org. Chem., 1993, 58(8), 2043-2045.
21. Tu, H.; Powers, J. P.; Liu, J.; Ursu, S.; Sudom, A.; Yan, X.; Xu, H.; Meininger, D.; DeGraffenreid, M.; He, X.; Jaen, J. C.; Sun, D.; Labelle, M.; Yamamoto, H.; Shan, B.; Walker, N. P. C.; Wang, Z. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta -hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem., 2008, 16(19), 8922-8931.
22. Stewart, P. M.; Wallace, A. M.; Atherden, S. M.; Shearing, C. H.; Edwards, C. R. W. Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11beta hydroxysteroid dehydrogenase activity in man. Clin. Sci., 1990, 78(1), 49-54.
23. Barf, T.; Vallgårda, J.; Emond, R.; Haeggstroem, C.; Kurz, G.; Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom, L.; Edling, N.; Roenquist-Nii, Y.; Oehman, B.; Alberts, P.; Abrahmsen, L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. discovery of potent and selective inhibitors of the 11Beta -hydroxysteroid dehydrogenase type 1. J. Med. Chem., 2002, 45(18), 3813-3815.
24. Vicker, N.; Su, X.; Lawrence, H.; Cruttenden, A.; Purohit, A.; Reed, M. J.; Potter, B. V. L. A novel 18beta -glycyrrhetinic acid analogue as a potent and selective inhibitor of 11beta hydroxysteroid dehydrogenase 2. Bioorg. Med. Chem. Lett., 2004, 14(12), 3263-3267.
25. Su, X.; Lawrence, H.; Ganeshapillai, D.; Cruttenden, A.; Purohit, A.; Reed, M. J.; Vicker, N.; Potter, B. V. L. Novel 18beta glycyrrhetinic acid analogues as potent and selective inhibitors of 11beta -hydroxysteroid dehydrogenases. Bioorg. Med. Chem., 2004, 12(16), 4439-4457.
26. Classen-Houben, D.; Schuster, D.; Da Cunha, T.; Odermatt, A.; Wolber, G.; Jordis, U.; Kueenburg, B. Selective inhibition of 11beta -hydroxysteroid dehydrogenase 1 by 18alpha -glycyrrhetinic acid but not 18beta -glycyrrhetinic acid. J. Steroid Biochem. Mol. Biol., 2009, 113(3-5), 248-252.
27. Beseda, I.; Czollner, L.; Shah, P. S.; Khunt, R.; Gaware, R.; Kosma, P.; Stanetty, C.; del Ruiz-Ruiz, M. C.; Amer, H.; Mereiter, K.; Da Cunha, T.; Odermatt, A.; Classen-Houben, D.; Jordis, U. Synthesis of glycyrrhetinic acid derivatives for the treatment of metabolic diseases. Bioorg. Med. Chem., 2010, 18(1), 433-454.
28. Tice, C. M.; Zhao, W.; Xu, Z.; Cacatian, S. T.; Simpson, R. D.; Ye, Y.-J.; Singh, S. B.; McKeever, B. M.; Lindblom, P.; Guo, J.; Krosky, P. M.; Kruk, B. A.; Berbaum, J.; Harrison, R. K.; Johnson, J. J.; Bukhtiyarov, Y.; Panemangalore, R.; Scott, B. B.; Zhao, Y.; Bruno, J. G.; Zhuang, L.; McGeehan, G. M.; He, W.; Claremon, D. A. Spirocyclic ureas: Orally bioavailable 11b-HSD1 inhibitors identified by computer-aided drug design. Bioorg. Med. Chem. Lett., 2010, 20(3), 881-886.
29. Tomkinson, G.P. Novel crystalline forms of 4-[4-(2- adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl] benzoic acid and their pharmaceutical use for inhibition of 11beta HSD1. WO 2009/098501, February 3, 2009.
30. Packer, M.; Scott, J. S.; Stocker, A.; Whittamore, P. R. O. Preparation of 4-[4-(2-adamantylcarbamoyl)-5-tert-butylpyrazol-1-yl] benzoic acid as 11beta HSD1 inhibitor. WO 2009/060232, November 5, 2009.
31. McCoull, W.; Packer, M.; Scott, J. S.; Whittamore, P. R. O. Preparation of (1R,5S,6r)-3-[5-(adamantan-2-ylcarbamoyl)-6-(methylthio)pyridin-2-yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid as 11beta HSD1 inhibitor. WO 2009/056881, October 29, 2009.
32. Taylor, A.; Irwin, N.; McKillop, A. M.; Flatt, P. R.; Gault, V. A. Sub-chronic administration of the 11beta -HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity. Biol. Chem., 2008, 389(4), 441-445.
33. Livingstone, D. E. W.; Walker, B. R. Is 11beta -hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J. Pharmacol. Exper. Ther., 2003, 305(1), 167-172.
34. Stewart, P.M.; Wallace, A.M.; Atherden, S.M.; Shearing, C.H.; Edwards, C.R. Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11 beta- hydroxysteroid dehydrogenase activity in man. Clin. Sci., 1990, 78(1), 49-54.
35. Andrews, R. C.; Rooyackers, O.; Walker, B. R. Effects of the 11beta -hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metabol., 2003, 88(1), 285-291.
36. Sandeep, T. C.; Andrew, R.; Homer, N. Z. M.; Andrews, R. C.; Smith, K.; Walker, B. R. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta - hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes, 2005, 54(3), 872-879.
37. Bjorkman, S. Prediction of the volume of distribution of a drug: Which tissue-plasma partition coefficients are needed? J. Pharm. Pharmacol.,2002, 54(9), 1237-1245.
38. Saiah, E. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-HSD1 inhibitors. Curr.Med. Chem., 2008, 15(7), 642-649.
39. Boyle, C. D.; Kowalski, T. J. 11Beta -hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Expert Opin. Ther. Pat., 2009, 19(6), 801-825.
40. Olson, S.; Aster, S. D.; Brown, K.; Carbin, L.; Graham, D. W.; Hermanowski-Vosatka, A.; LeGrand, C. B.; Mundt, S. S.; Robbins, M. A.; Schaeffer, J. M.; Slossberg, L. H.; Szymonifka, M. J.; Thieringer, R.; Wright, S. D.; Balkovec, J. M. Adamantyl triazoles as selective inhibitors of 11beta -hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett., 2005, 15(19), 4359-4362.
41. Gu, X.; Dragovic, J.; Koo, G. C.; Koprak, S. L.; LeGrand, C.; Mundt, S. S.; Shah, K.; Springer, M. S.; Tan, E. Y.; Thieringer, R.; Hermanowski-Vosatka, A.; Zokian, H. J.; Balkovec, J. M.; Waddell, S. T. Discovery of 4-heteroarylbicyclo [2.2.2] octyltriazoles as potent and selective inhibitors of 11beta -HSD1: Novel therapeutic agents for the treatment of metabolic syndrome. Bioorg. Med. Chem. Lett., 2005, 15(23), 5266-5269.
42. Zhu, Y.; Olson, S. H.; Graham, D.; Patel, G.; Hermanowski-Vosatka, A.; Mundt, S.; Shah, K.; Springer, M.; Thieringer, R.; Wright, S.; Xiao, J.; Zokian, H.; Dragovic, J.; Balkovec, J. M. Phenylcyclobutyl triazoles as selective inhibitors of 11beta hydroxysteroid dehydrogenase type I. Bioorg. Med. Chem. Lett., 2008, 18(11), 3412-3416.
43. Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, M.; Koo, G. C.; Le Grand, C. B.; Li, Z.; Metzger, J. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, J. M.; Shah, K.; Springer, M. S.; Strack, A. M.; Strowski, M.; Wu, K.; Wu, T.; Xiao, J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. 11Beta -HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exper. Med., 2005, 202(4), 517-527.
44. Patel, J. R.; Shuai, Q.; Dinges, J.; Winn, M.; Pliushchev, M.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Pan, L.; Wagaw, S.; Engstrom, K.; Kerdesky, F. A.; Longenecker, K.; Judge, R.; Qin, W.; Imade, H. M.; Stolarik, D.; Beno, D. W. A.; Brune, M.; Chovan, L. E.; Sham, H. L.; Jacobson, P.; Link, J. T. Discovery of adamantane ethers as inhibitors of 11beta -HSD-1: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2007, 17(3), 750-755.
45. Sorensen, B.; Winn, M.; Rohde, J.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K.; Chiou, W.; Stolarik, D.; Imade, H.; Pan, L.; Deng, X.; Chovan, L.; Longenecker, K.; Judge, R.; Qin, W.; Brune, M.; Camp, H.; Frevert, E. U.; Jacobson, P.; Link, J. T. Adamantane sulfone and sulfonamide 11-Beta -HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(2), 527-532.
46. Rohde, J. J.; Pliushchev, M. A.; Sorensen, B. K.; Wodka, D.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K. M.; Chiou, W. J.; Pan, L.; Deng, X.; Chovan, L. E.; Ramaiya, A.; Mullally, M.; Henry, R. F.; Stolarik, D. F.; Imade, H. M.; Marsh, K. C.; Beno, D. W. A.; Fey, T. A.; Droz, B. A.; Brune, M. E.; Camp, H. S.; Sham, H. L.; Frevert, E. U.; Jacobson, P. B.; Link, J. T. Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11Beta -hydroxysteroid dehydrogenase type 1 inhibitors. J. Med. Chem., 2007, 50(1), 149-164.
47. Yeh, S. C.; Kurukulasuriya, R.; Madar, D.; Patel Jyoti, R.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Jacobson, P.; Sham Hing, L.; Link, J. T. Synthesis and structural activity relationship of 11betaHSD1 inhibitors with novel adamantane replacements. Bioorg. Med. Chem. Lett., 2006, 16(20), 5408-5413.
48. Sorensen, B.; Rohde, J.; Wang, J.; Fung, S.; Monzon, K.; Chiou, W.; Pan, L.; Deng, X.; Stolarik, D.; Frevert, E. U.; Jacobson, P.; Link, J. T. Adamantane 11-Beta -HSD-1 inhibitors: Application of an isocyanide multicomponent reaction. Bioorg. Med. Chem. Lett., 2006, 16(23), 5958-5962.
49. Wang, H.; Ruan, Z.; Li, J. J.; Simpkins, L. M.; Smirk, R. A.; Wu, S. C.; Hutchins, R. D.; Nirschl, D. S.; Van Kirk, K.; Cooper, C. B.; Sutton, J. C.; Ma, Z.; Golla, R.; Seethala, R.; Salyan, M. E. K.; Nayeem, A.; Krystek, S. R., Jr.; Sheriff, S.; Camac, D. M.; Morin, P. E.; Carpenter, B.; Robl, J. A.; Zahler, R.; Gordon, D. A.; Hamann, L. G., Pyridine amides as potent and selective inhibitors of 11beta -hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett.,2008, 18(11), 3168-3172.
50. McMinn, D. L.; Rew, Y.; Sudom, A.; Caille, S.; De Graffenreid, M.; He, X.; Hungate, R.; Jiang, B.; Jaen, J.; Julian, L. D.; Kaizerman, J.; Novak, P.; Sun, D.; Tu, H.; Ursu, S.; Walker, N. P. C.; Yan, X.; Ye, Q.; Wang, Z.; Powers, J. P. Optimization of novel di- substituted cyclohexylbenzamide derivatives as potent 11beta - HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(5), 1446-1450.
51. Rew, Y.; McMinn, D. L.; Wang, Z.; He, X.; Hungate, R. W.; Jaen, J. C.; Sudom, A.; Sun, D.; Tu, H.; Ursu, S.; Villemure, E.; Walker, N. P. C.; Yan, X.; Ye, Q.; Powers, J. P. Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11beta - HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(6), 1797-1801.
52. Julian, L. D.; Wang, Z.; Bostick, T.; Caille, S.; Choi, R.; DeGraf-Fenreid, M.; Di, Y.; He, X.; Hungate, R. W.; Jaen, J. C.; Liu, J.; Monshouwer, M.; McMinn, D.; Rew, Y.; Sudom, A.; Sun, D.; Tu, H.; Ursu, S.; Walker, N.; Yan, X.; Ye, Q.; Powers, J. P. Discovery of novel, potent benzamide inhibitors of 11Beta -hydroxysteroid dehydrogenase type 1 (11beta -HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model. J. Med. Chem., 2008, 51(13), 3953-3960.
53. Roche, D.; Carniato, D.; Leriche, C.; Lepifre, F.; Christmann-Franck, S.; Graedler, U.; Charon, C.; Bozec, S.; Doare, L.; Schmidlin, F.; Lecomte, M.; Valeur, E. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta -hydroxysteroid dehydrogenase type I. Bioorg. Med. Chem. Lett.,2009, 19(10), 2674-2678.
54. Lepifre, F.; Christmann-Franck, S.; Roche, D.; Leriche, C.; Carniato, D.; Charon, C.; Bozec, S.; Doare, L.; Schmidlin, F.; Lecomte, M.; Valeur, E. Discovery and structure-guided drug design of inhibitors of 11.beta -hydroxysteroid-dehydrogenase type I based on a spiro-carboxamide scaffold. Bioorg. Med. Chem. Lett., 2009, 19(13), 3682-3685.
55. Yang, H.; Shen, Y.; Chen, J.; Jiang, Q.; Leng, Y.; Shen, J. Structure-based virtual screening for identification of novel 11beta - HSD1 inhibitors. Eur. J. Med. Chem., 2009, 44(3), 1167-1171.
56. Zhang, X.; Zhou, Y.; Shen, Y.; Du, L.-l.; Chen, J.-h.; Leng, Y.; Shen, J.-h. Derivatives of (phenylsulfonamido-methyl)nicotine and (phenylsulfonamido-methyl)thiazole as novel 11beta-hydroxy-steroid dehydrogenase type 1 inhibitors: synthesis and biological activities in vitro. Acta Pharmacol. Sinica, 2009, 30(9), 1344-1350.
57. Zhang, X.; Zhou, Z.; Yang, H.; Chen, J.; Feng, Y.; Du, L.; Leng, Y.; Shen, J.; 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta -hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice. Bioorg. Med. Chem. Lett.,2009, 19(15), 4455-4458.
58. Yeh, V. S. C.; Patel, J. R.; Yong, H.; Kurukulasuriya, R.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Stolarik, D.; Imade, H.; Beno, D.; Brune, M.; Jacobson, P.; Sham, H.; Link, J. T. Synthesis and biological evaluation of heterocycle containing adamantane 11beta -HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(20), 5414-5419.
59. Yeh, V. S. C.; Kurukulasuriya, R.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Stolarik, D.; Imade, H.; Shapiro, R.; Knourek-Segel, V.; Bush, E.; Wilcox, D.; Nguyen, P. T.; Brune, M.; Jacobson, P.; Link, J. T. Discovery of orally active butyrolactam 11beta -HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(21), 5555-5560.
60. Johansson, L.; Fotsch, C.; Bartberger, M. D.; Castro, V. M.; Chen, M.; Emery, M.; Gustafsson, S.; Hale, C.; Hickman, D.; Homan, E.; Jordan, S. R.; Komorowski, R.; Li, A.; McRae, K.; Moniz, G.; Matsumoto, G.; Orihuela, C.; Palm, G.; Veniant, M.; Wang, M.; Williams, M.; Zhang, J., 2-Amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta -hydroxysteroid dehydrogenase type 1 inhibitors: Enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice. J. Med. Chem., 2008, 51(10), 2933-2943.
61. St. Jean, D. J., Jr.; Yuan, C.; Bercot, E. A.; Cupples, R.; Chen, M.; Fretland, J.; Hale, C.; Hungate, R. W.; Komorowski, R.; Veniant, M.; Wang, M.; Zhang, X.; Fotsch, C., 2-(S)-phenethylamino- thiazolones as potent, orally efficacious inhibitors of 11beta - hydroxysteroid dehydrogenase type 1. J. Med. Chem., 2007, 50(3), 429-432.
62. Hale, C.; Veniant, M.; Wang, Z.; Chen, M.; McCormick, J.; Cupples, R.; Hickman, D.; Min, X.; Sudom, A.; Xu, H.; Matsumoto, G.; Fotsch, C.; St. Jean, D. J. Jr.; Wang, M. Structural characterization and pharmacodynamic effects of an orally active 11beta - hydroxysteroid dehydrogenase type 1 inhibitor. Chem. Biol. Drug Des., 2008, 71(1), 36-44.
63. Fotsch, C.; Bartberger, M. D.; Bercot, E. A.; Chen, M.; Cupples, R.; Emery, M.; Fretland, J.; Guram, A.; Hale, C.; Han, N.; Hickman, D.; Hungate, R. W.; Hayashi, M.; Komorowski, R.; Liu, Q.; Matsumoto, G.; St. Jean, D. J.; Ursu, S.; Veniant, M.; Xu, G.; Ye, Q.; Yuan, C.; Zhang, J.; Zhang, X.; Tu, H.; Wang, M. Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta - hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane x receptor activity and exploring activity in a monkey pharma- codynamic model. J. Med. Chem., 2008, 51(24), 7953-7967.
64. Yuan, C.; St. Jean, D. J.; Liu, Q.; Cai, L.; Li, A.; Han, N.; Moniz, G.; Askew, B.; Hungate, R. W.; Johansson, L.; Tedenborg, L.; Pyring, D.; Williams, M.; Hale, C.; Chen, M.; Cupples, R.; Zhang, J.; Jordan, S.; Bartberger, M. D.; Sun, Y.; Emery, M.; Wang, M.; Fotsch, C. The discovery of 2 anilinothiazolones as 11beta -HSD1 inhibitors. Bioorg.Med. Chem. Lett., 2007, 17(22), 6056-6061
65. Fotsch, C.; Adams, J.; Bartberger, M.; Bercot, E. A.; Cai, L.; Castro, V. M.; Chen, M.; Cupples, R.; Emery, M.; Fretland, J.; Guram, A.; Gustafsson, S.; Hague, A.; Hale, C.; Han, N.; Hayashi, M.; Henriksson, M.; Hickman, D.; Homan, E.; Hungate, R. W.; Johansson, L.; Jordan, S.; Kaiser, C.; Komorowski, R.; Li, A.; Liu, Q.; Matsumoto, G.; McRae, K.; Moniz, G.; Palm, G.; Pyring, D.; St. Jean, D. J., Jr.; Sun, Y.; Sydow-Backman, M.; Tedenborg, L.; Tu, H.; Ursa, S.; Veniant, M.; Williams, M.; Xu, G.; Ye, Q.; Yuan, C.; Zhang, J.; Zhang, X.; Wang, M. Discovery of AMG 221: An 11beta -HSD1 inhibitor in the clinic for type 2 diabetes, MEDI- 029, 237th ACS National Meeting, Salt Lake City, UT, United States, March 22-26, 2009.
66. Caille, S.; Cui, S.; Hwang, T.-L.; Wang, X.; Faul, M. M. Two asymmetric syntheses of AMG 221, an inhibitor of 11.beta - hydroxysteroid dehydrogenase type 1. J. Org. Chem., 2009, 74(10), 3833-3842.
67. Sundbom, M.; Kaiser, C.; Bjoerkstrand, E.; Castro, V. M.; Larsson, C.; Selen, G.; Nyhem, C. S.; James, S. R. Inhibition of 11beta HSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeo- stasis in diabetic KKAy mice. BMC Pharmacol., 2008, 8, 3.
68. Lloyd, D. J.; Helmering, J.; Cordover, D.; Bowsman, M.; Chen, M.; Hale, C.; Fordstrom, P.; Zhou, M.; Wang, M.; Kaufman, S. A.; Veniant, M. M. Antidiabetic effects of 1 11beta -HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and athero- sclerosis. Diabetes Obes. Metabol., 2009, 11(7), 688-699.
69. Veniant, M. M.; Hale, C.; Komorowski, R.; Chen, M. M.; St. Jean, D. J.; Fotsch, C.; Wang, M. Time of the day for 11.beta -HSD1 in- hibition plays a role in improving glucose homeostasis in DIO mice. Diabetes Obes. Metabol., 2009, 11(2), 109-117.
70. Sun, D.; Wang, Z.; Di, Y.; Jaen, J. C.; Labelle, M.; Ma, J.; Miao, S.; Sudom, A.; Tang, L.; Tomooka, C. S.; Tu, H.; Ursu, S.; Walker, N.; Yan, X.; Ye, Q.; Powers, J. P. Discovery and Initial SAR of arylsulfonylpiperazine inhibitors of 11beta -hydroxysteroid dehydrogenase type 1 (11beta -HSD1). Bioorg. Med. Chem. Lett., 2008, 18(12), 3513-3516.
71. Xiang, J.; Wan, Z.-K.; Li, H.-Q.; Ipek, M.; Binnun, E.; Nunez, J.; Chen, L.; McKew, J. C.; Mansour, T. S.; Xu, X.; Suri, V.; Tam, M.; Xing, Y.; Li, X.; Hahm, S.; Tobin, J.; Saiah, E. Piperazine sulfonamides as potent, selective, and orally available 11beta - hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model. J. Med. Chem., 2008, 51(14), 4068-4071.
72. Wan, Z.-K.; Chenail, E.; Xiang, J.; Li, H.-Q.; Ipek, M.; Bard, J.; Svenson, K.; Mansour, T. S.; Xu, X.; Tian, X.; Suri, V.; Hahm, S.; Xing, Y.; Johnson, C. E.; Li, X.; Qadri, A.; Panza, D.; Perreault, M.; Tobin, J. F.; Saiah, E. Efficacious 11Î -hydroxysteroid dehy- drogenase type I inhibitors in the diet-induced obesity mouse model. J. Med. Chem., 2009, 52(17), 5449-5461.
73. Siu, M.; Johnson, T. O.; Wang, Y.; Nair, S. K.; Taylor, W. D.; Cripps, S. J.; Matthews, J. J.; Edwards, M. P.; Pauly, T. A.; Ermolieff, J.; Castro, A.; Hosea, N. A.; La Paglia, A.; Fanjul, A. N.; Vogel, J. E. N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11.beta -hydroxysteroid dehydrogenase type 1: Discovery of PF-915275. Bioorg. Med. Chem. Lett.,2009, 19(13), 3493-3497.
74. Bhat, B. G.; Hosea, N.; Fanjul, A.; Herrera, J.; Chapman, J.; Thalacker, F.; Stewart, P. M.; Rejto, P. A. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyanobiphenyl-4-sulfonic acid(6-amino-pyridin-2- yl)amide (PF-915275), an inhibitor of 11beta -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J. Pharmacol. Exp. Ther., 2008, 324(1), 299-305.
75. Courtney, R.; Stewart, P. M.; Toh, M.; Ndongo, M.-N.; Calle, R. A.; Hirshberg, B. Modulation of 11beta -Hydroxysteroid dehydro- genase (11beta HSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11beta HSD1 inhibitor. J. Clin. Endocrinol.Metabol., 2008, 93(2), 550-556.
76. Alberts, P.; Nilsson, C.; Selen, G.; Engblom, L. O. M.; Edling, N. H. M.; Norling, S.; Klingstroem, G.; Larsson, C.; Forsgren, M.; Ashkzari, M.; Nilsson, C. E.; Fiedler, M.; Bergqvist, E.; Oehman, B.; Bjoerkstrand, E.; Abrahmsen, L. B. Selective inhibition of 11beta -hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology, 2003, 144(11), 4755-4762.
77. Alberts, P.; Engblom, L.; Edling, N.; Forsgren, M.; Klingstroem, G.; Larsson, C.; Roenquist-Nii, Y.; Oehman, B.; Abrahmsen, L. Selective inhibition of 11beta -hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia, 2002, 45(11), 1528-1532.
78. Wang, S. J. Y.; Birtles, S.; Schoolmeester, J.; Swales, J.; Moody, G.; Hislop, D.; O'Dowd, J.; Smith, D. M.; Turnbull, A. V.; Arch, J. R. S. Inhibition of 11beta -hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia, 2006, 49(6), 1333-1337.
79. Accelrys, Inc., San Diego, CA, 92121.
80. Huber, R.; Banarer, S.; Fonseca, V.; Inzucchi, S.; Yao, W.; Hollis, G.; Flores, R.; Levy, R.; Williams, B.; Rosenstock, J. In: 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), Vienna, 2009, Vol. 172.
81. Japan Tobacco Inc. Clinical development JTT-654. http://www.jt.com/investors/results/pharmaceuticals/pdf/P.L.20091 029_E.pdf (Accessed on: 23-Jan-2010)
82. ClinicalTrials.gov BMS-816336. http://clinicaltrials.gov/ct2/show/ NCT00979368 (Accessed on: 23-Jan-2010)
83. Wyeth Clinical Trial Listing HSD-016. http://www.wyeth.com/ ClinicalTrialListings?query=Healthy%20Subjects (Accessed on: 23-Jan-2010)
84. ClinicalTrials.gov AZD4017. http://www.clinicaltrials.gov/ct2/ results?term=AZD4017 (Accessed on: 23-Jan-2010)
85. Roche Group early-stage development pipeline RG4929. http://www.gene.com/gene/pipeline/pdf/roche_group_pipeline.pdf (Accessed on: 23-Jan-2010)